by Comite Web | Oct 1, 2026 | Sin categorizar
Speaker: Dr. Remy Nicolley
Institution: Pancreatic Cancer Heterogeneity & Translational Genomics Group | Center for Inflammation Research | Paris, France
Title:“Morphomolecular Phenotyping of Pancreatic Tumors”
Description
On October 15 at 3:00 p.m. CET, ALIPANC will hold another session of the ALIPANC Seminar Series, an initiative designed to promote scientific exchange and highlight the most innovative advances in pancreatic cancer research.
Dr. Remy Nicolle is the principal investigator of the
Pancreatic Cancer Heterogeneity & Translational Genomics group at the
Centre de Recherche sur l’Inflammation (INSERM, Paris, France).
Access
This seminar is open to the public; the registration link will be shared shortly.
For any additional information, please contact info@alipanc.org to request the meeting link.
by Comite Web | Sep 17, 2026 | Sin categorizar
An international team—with significant participation from the PADO group at the ICO and IDIBELL, which includes several members of ALIPANC—has developed an epidemiological risk score for the early detection of pancreatic cancer, one of the deadliest cancers due to late diagnosis. The study, published in the International Journal of Epidemiology, is based on 24 known risk factors—such as age, smoking, diabetes, chronic pancreatitis, and family history—which help identify individuals most likely to develop the disease. The score was applied to a prospective cohort of 178 individuals with a high family risk from four European centers, as part of the IMAGene project, who were evaluated using magnetic resonance imaging. The results show that higher scores were associated with a greater number of potentially malignant lesions. External validation, conducted with nearly 300,000 participants from the UK Biobank, confirmed these associations. The authors conclude that this could be a feasible, noninvasive, and low-cost tool for risk stratification, although further studies will be needed before it can be applied clinically.
PMID: 42160519
doi: 10.1093/ije/dyag064
by Comite Web | Sep 17, 2026 | Sin categorizar
The multicenter study included 672 patients treated with first-line chemotherapy. A low SIRI score (≤2.3) was associated with longer overall survival (14.0 vs. 9.2 months). It was also associated with longer progression-free survival (5.9 vs. 3.9 months) and a higher tumor response rate (37% vs. 25%). In addition to the classic cutoff point, the SIRI was analyzed as a continuous variable. This analysis revealed a nonlinear relationship between increasing SIRI and a worse prognosis. A high SIRI score was also associated with a higher hepatic tumor burden and cachexia.
An open-access web calculator allows users to explore this continuous prognostic gradient on an individualized basis: https://pantheia-siri.shinyapps.io/calc/.
The collaborative study was led by Vilma Pacheco-Barcia and has been published in the journals *Pancreatology* and *Clinical Translational Oncology*.
PMID 42601286, 42690293
doi: 10.1016/j.pan.2026.08.008
doi: 10.1007/s12094-026-04554-8
by Comite Web | Sep 17, 2026 | Sin categorizar
Cancer stem cells (CSCs) are a highly tumorigenic population of pancreatic ductal adenocarcinoma (PDAC) cells that contribute to tumor progression, metastasis, therapy resistance and disease relapse. In this study, Pérez-Ruiz and colleagues investigated apMNKQ2, a DNA aptamer targeting MNK1, a protein involved in PDAC progression and CSC maintenance. Using patient-derived models, the authors showed that apMNKQ2 impaired pancreatic cancer cell growth and several properties associated with tumor aggressiveness. Importantly, the aptamer strongly affected the CSC population, markedly reducing its ability to self-renew and initiate new tumors. The study also demonstrated that apMNKQ2 can reach tumors following systemic administration and showed a favorable safety profile in preclinical models. Together, these findings identify MNK1 as a promising therapeutic vulnerability in pancreatic CSCs and support the further development of apMNKQ2 as a potential new therapeutic strategy for PDAC.
The study was led by Bruno Sainz from the Instituto de Investigaciones Biomédicas, Madrid, and published in the Journal of Biomedical Sciences.
PMID 42410607
doi: 10.1186/s12929-026-01275-6
by Comite Web | Sep 17, 2026 | Sin categorizar
The ESPACE consortium presents a comprehensive multi-omic atlas of the human pancreas, profiling more than 4 million cells from 57 donors across fetal development, adult homeostasis, and type 2 diabetes.
With a particular focus on the exocrine compartment, the study resolves the heterogeneity of acinar and ductal cells and reveals a transcriptional continuum connecting these identities. At the root of this continuum, they identify and validate in situ a rare population of plastic centroacinar-like cells with acinar-to-ductal metaplasia and developmental progenitor-like features.
These findings provide a new framework for investigating cellular plasticity in the healthy human pancreas and how these states may relate to processes involved in pancreatic injury, regeneration, and disease, including pancreatic cancer.
The ESPACE atlas is openly available to the community through an interactive web portal, where researchers can explore and access the single-cell datasets and associated cell states. Elisabet Mereu, from the Institut Josep Carreras in Badalona, is the first author of the paper, published in Cell Metabolism.
PMID 42586061
https://doi.org/10.1016/j.cmet.2026.07.023
Explore the ESPACE Human Pancreas Atlas: singlecell.charite.de
by Comite Web | Jul 20, 2026 | Sin categorizar
5th ALIPANC Charity Gala
Friday, November 20, at 8:00 p.m.
Real Casino de Madrid
C. Alcalá, 15, Centro, 28014 Madrid
Donation: 200 € per person
Join the fight against pancreatic cancer
On behalf of the Pancreatic Cancer Research Alliance in Spain (ALIPANC), we would like to invite you to participate in the 5th edition of our Charity Gala, a fundraising event held in conjunction with International Pancreatic Cancer Day.
This dinner aims to:
- Raise awareness about ALIPANC’s mission
- Collect funds for research
- Strengthen the commitment of our benefactors
ALIPANC brings together over 160 researchers from Spain and Portugal, working across hospitals and research centers in multicenter, multidisciplinary studies to improve the diagnosis, treatment, and survival of pancreatic cancer patients.
How can you help?
- Attend the gala: Share a meaningful evening with researchers, patients, and representatives from the business and public sectors.
- Support through “fila cero”: Contribute even if you cannot attend in person.
- Spread the word: Help raise public awareness about this disease.
Registration
Registration form https://forms.gle/EDhZkmVo7axLodzRA
Payment Options
- Bank transfer
IBAN: ES31 0182 9769 5102 0055 3107 - Bizum (Donate to NGOs):
Code: NGO 10456
Formal attire requested.
